+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Regulatory T Cell"

Vulvar Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Vulvar Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
From
CCR8-Targeted Antibody Immunotherapy Pipeline Review - Product Thumbnail Image

CCR8-Targeted Antibody Immunotherapy Pipeline Review

  • Report
  • September 2025
  • Global
From
From
From
CTLA-4 inhibitors- Competitive landscape, 2023 - Product Thumbnail Image

CTLA-4 inhibitors- Competitive landscape, 2023

  • Report
  • May 2023
  • 220 Pages
  • Global
From
From
Immunology of Pregnancy 2013 - Product Thumbnail Image

Immunology of Pregnancy 2013

  • Book
  • November 2013
  • 982 Pages
Loading Indicator

Regulatory T Cells (Tregs) are a type of immune cell that play an important role in controlling the body's immune response. They are used in biotechnology to treat a variety of diseases, including autoimmune diseases, allergies, and cancer. Tregs can be used to suppress the immune system, allowing the body to tolerate foreign substances, such as transplanted organs, or to reduce inflammation. They can also be used to stimulate the immune system to fight cancer or other diseases. Tregs are typically isolated from a patient's own blood or tissue, or from donor sources. They can then be modified to express specific proteins or receptors, or to produce cytokines, to enhance their therapeutic effects. Tregs can also be engineered to express chimeric antigen receptors (CARs) to target specific cancer cells. The Treg market is growing rapidly, driven by increasing demand for treatments for autoimmune diseases, allergies, and cancer. Companies in the market include Celgene, Novartis, Kite Pharma, and Juno Therapeutics. Show Less Read more